|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Enzon Pharmaceuticals, Inc. |
|---|---|
| Information provided by: | Enzon Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT00023166 |
Purpose
Studies of PEG-paclitaxel have been terminated
| Condition | Intervention | Phase |
|---|---|---|
|
Neoplasm Lymphomas Neoplasm Metastasis |
Drug: PEG-paclitaxel |
Phase I |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
None - Study has been terminated.
Contacts and Locations
More Information
| Study ID Numbers: | PTX-5001 |
| Study First Received: | August 24, 2001 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00023166 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Phase I Open label Safety/efficacy Lymphomas |
Advanced primary and/or metastatic solid tumors Neoplasms Neoplasm metastasis |
|
Neoplasms by Histologic Type Immunoproliferative Disorders Molecular Mechanisms of Pharmacological Action Immune System Diseases Antineoplastic Agents Mitosis Modulators Antimitotic Agents Pharmacologic Actions Lymphatic Diseases Neoplasms |
Neoplastic Processes Pathologic Processes Paclitaxel Therapeutic Uses Tubulin Modulators Neoplasm Metastasis Lymphoproliferative Disorders Antineoplastic Agents, Phytogenic Lymphoma |